Qiming Venture Partners Weekly | Portfolio Company Updates Vol. 27, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Editor's Note: The "Qiming Weekly" column publishes regularly every week, rounding up funding news and development updates from Qiming Venture Partners' portfolio companies.
In the wave of technology and innovation, every step entrepreneurs take is worth documenting. Qiming Venture Partners will continue to accelerate and empower founders, and invites you to follow along as we track milestone moments for our portfolio companies.
Major Partnerships
01/
DeepWay Signs Agreement with New Zealand Partner
and Completes First Vehicle Deliveries
Recently, Qiming Venture Partners portfolio company DeepWay formally signed a smart new-energy heavy-duty truck distribution agreement with a local New Zealand partner and successfully completed first vehicle deliveries. This important partnership marks a key step for DeepWay into the Southern Hemisphere market, building on its successful expansion into Australia and further extending its reach into premium international markets.
At the signing ceremony, the New Zealand partner got up close with DeepWay's smart new-energy heavy-duty trucks, gaining deep understanding of their core advantages in cab-forward structural design, intelligent driving assistance systems, battery layout, and long-range capability. Through test drives, the customer experienced firsthand the vehicle's excellent handling stability, energy consumption control, and driving comfort — earning high praise.
02/
Liuzhou Iron & Steel Group Partners with Shangyue Technology
to Successfully Launch E-Procurement Mall Project
Recently, Liuzhou Iron & Steel Co., Ltd. ("Liugang Group") held a successful kickoff meeting for its e-procurement mall project. Qiming Venture Partners portfolio company Shangyue Technology founder and CEO Feng Miao attended the kickoff meeting alongside project team members from both sides.
Feng Miao noted that with excess capacity across industries, digitalization and intelligentization have become inevitable choices for enterprises to enhance competitiveness and reduce procurement costs. Shangyue Technology will fully leverage its expertise in procurement digitalization to drive up the catalog-based procurement ratio for Liugang Group's MRO purchasing, enabling digital transformation and cost reduction while ensuring compliance. He expressed hope that through deep collaboration, the two sides would jointly build a benchmark project for digital transformation of procurement in the steel industry.
R&D Progress
01/
Abbisko Pharma's Innovative PRMT5*MTA Inhibitor
ABSK131 Completes First Patient Dosing in Phase 1 Trial
Recently, Qiming Venture Partners portfolio company Abbisko Pharma (02256.HK) announced that its independently developed highly selective small-molecule PRMT5*MTA inhibitor ABSK131 has completed first patient dosing. In March this year, ABSK131 received clinical trial approval from the Center for Drug Evaluation, NMPA (CDE) for the treatment of patients with advanced solid tumors. In December last year, its clinical trial was approved by the FDA.
ABSK131 demonstrates potent anti-tumor activity. In preclinical studies, it showed excellent selectivity for MTAP-deficient tumor cells. Preclinical research indicates that ABSK131 has favorable drug metabolism and pharmacokinetic properties when administered orally.
02/
SinoCellTech's SCT640C Injection Approved in China
for Phase 1 Clinical Trial in Adult Rheumatoid Arthritis
Recently, Qiming Venture Partners portfolio company SinoCellTech (688520.SH) received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration, approving the initiation of clinical trials for its independently developed product SCT640C injection in adult rheumatoid arthritis (RA).
Rheumatoid arthritis is a systemic autoimmune disease characterized by chronic erosive arthritis as its primary clinical manifestation. It is a highly disabling condition that can be complicated by pulmonary disease, cardiovascular and cerebrovascular disease, osteoporosis, and malignancy. Global RA incidence is approximately 0.5%-1%, with incidence in mainland China estimated at 0.4-2%, suggesting over 5 million current RA patients in China. SCT640C injection is a monoclonal antibody injection independently developed by SinoCellTech with differentiated competitive advantages for the treatment of autoimmune diseases.
03/
AusperBio's Oligonucleotide Drug AHB-137
Receives NMPA Approval to Initiate Phase 3 Clinical Trial
Recently, Qiming Venture Partners portfolio company AusperBio announced that the Center for Drug Evaluation, NMPA (CDE) has approved its core candidate drug AHB-137 to initiate Phase 3 clinical trials.
This Phase 3 trial is a randomized, double-blind, multi-center study conducted in China, designed to evaluate the efficacy and safety of 24-week treatment with 300mg AHB-137 in HBeAg-negative chronic hepatitis B patients receiving stable nucleos(t)ide analogue therapy.
AHB-137 is a non-conjugated antisense oligonucleotide (ASO) drug with the potential to become a cornerstone therapy for functional cure of chronic hepatitis B, and has garnered broad attention and recognition for its notably outstanding efficacy and safety profile.
Product Launches
01/
Zhipu AI Releases Next-Generation Flagship Model GLM-4.5
Recently, Qiming Venture Partners portfolio company Zhipu AI released its next-generation flagship model GLM-4.5, a foundation model purpose-built for agent applications. The model was open-sourced simultaneously on Hugging Face and ModelScope, with model weights released under the MIT License.
GLM-4.5 achieves open-source SOTA on combined capabilities spanning reasoning, coding, and agent tasks. In human-evaluated comparisons of real-world coding agents, it ranks best-in-class in China. Built on a Mixture-of-Experts (MoE) architecture, GLM-4.5 has 355 billion total parameters with 32 billion active parameters; GLM-4.5-Air has 106 billion total parameters with 12 billion active parameters. The model features a thinking mode for complex reasoning and tool use, plus a non-thinking mode for instant response. It delivers high speed at low cost, with the high-speed version reaching up to 100 tokens/second.
02/
StepFun Releases Next-Generation Foundation Model Step 3
and Initiates Formation of Model-Chip Ecosystem Innovation Alliance
Recently, Qiming Venture Partners portfolio company StepFun officially released its next-generation foundation model, Step 3. As StepFun's flagship base model, Step 3 balances intelligence and efficiency, aiming to build the most application-ready model for the inference era. Step 3 will be open-sourced globally for enterprises and developers on July 31, contributing the world's strongest open-source multimodal reasoning model.
At the same time, StepFun also announced the formation of the "Model-Chip Ecosystem Innovation Alliance" alongside multiple leading Chinese chip and platform companies, including Qiming Venture Partners portfolio companies Biren Technology and Infinigence AI. The alliance will accelerate large model application deployment by driving joint innovation across the model and chip industry chains.
Daxin Jiang, founder and CEO of StepFun, said: "The rapid iteration from Step 1 to Step 2 prompted us to think deeply about what makes a model truly suitable for applications. As large models enter the reinforcement learning development phase, next-generation reasoning models have become mainstream. While the performance gains are significant, does this fully equate to model value? Facing this industry-wide question, we must return to customer needs, ground ourselves in real application scenarios, and explore viable paths for model innovation to reach production. This was our starting point in developing the new-generation Step 3 foundation model."
03/
Shengshu Technology and Tsinghua University Release
Embodied Video Foundation Model Vidar
Recently, Vidar, an embodied video foundation model jointly developed by Tsinghua University and Qiming Venture Partners portfolio company Shengshu Technology, was officially released. Through an innovative "video foundation model + embodied artificial intelligence" technical approach, the model effectively achieves low-cost, few-shot robot training — requiring only 20 minutes of real robot training data to reach high generalization, dramatically lowering the data barrier for large-scale generalization on robots. This provides an innovative solution to the data dilemma that has plagued the embodied AI industry for years, and brings genuine hope for true generalization in robots executing complex tasks in the real world.
As a major breakthrough extending the video foundation model Vidu into embodied intelligence, Vidar is the world's first multi-view embodied foundation model to systematically transfer video understanding capabilities to physical decision-making based on a general video foundation model. The model innovatively constructs a multi-view video prediction framework supporting dual-arm collaborative tasks for robots, demonstrating significant few-shot learning advantages while maintaining SOTA performance. The fine-tuned model can complete multi-view dual-arm tasks, achieving "say the instruction, do the task."
This research breakthrough significantly advances robot capabilities in two areas: multi-task operation and flexible adaptation to environmental changes, laying solid technical groundwork for future service robots to perform in complex real-world environments such as homes, hospitals, and factories. It also means that from algorithmic training in virtual worlds to autonomous action in real environments, Vidar is building the critical bridge that finally allows AI to "get its feet on the ground" and serve our physical world.
04/
Shanghai Academy of AI for Science, Fudan University, and Infinite Light-Year Launch
NovaInspire Scientist-Centered AI Open Platform
Recently, the Shanghai Academy of AI for Science, Fudan University, and Qiming Venture Partners portfolio company Infinite Light-Year launched the NovaInspire Scientist-Centered AI Open Platform (NovaInspire: Scientist-Centered AI Open Platform). The platform is deeply focused on a core need of researchers: letting more powerful and more accessible AI infrastructure and collaboration platforms naturally integrate into the full research workflow, helping more scientists step away from technical minutiae, focus on the essence of science, and join hands to accelerate the exploration of the unknown.
Infinite Light-Year specially built NovaInspire Lab for the platform, using intelligent fault tolerance, dynamic deployment, GPU/CPU fusion, and other technologies to improve efficiency for cutting-edge scientific model R&D, constructing a high-stability, high-efficiency computing platform. From computing scheduling to scenario adaptation, from stability assurance to domestic hardware compatibility, it builds a "full-chain computing foundation," making AI an "invisible assistant" for scientific research.
The launch of the NovaInspire Scientist-Centered AI Open Platform marks the entry of AI for science into a 2.0 era driven by collaborative ecosystems and systematic breakthroughs. Using the NovaInspire platform as a technical fulcrum, Infinite Light-Year injects efficient intelligent computing and general AI technology infrastructure into NovaInspire, working with Fudan University, the Shanghai Academy of AI for Science, and others to build an open collaboration network, promoting the development and prosperity of a scientist-centered scientific innovation network that integrates "frontier exploration and application of results."
05/
Houmo AI Releases New Edge AI Chip
Houmo Manjie® M50 and Hardware Portfolio
Recently, Qiming Venture Partners portfolio company Houmo AI officially released its new edge AI chip for large models — the Houmo Manjie® M50, simultaneously launching the LiQing™ series M.2 cards, the LiMou® series accelerator cards, and computing boxes, forming a complete product matrix covering mobile terminals and edge scenarios. The M50 chip achieves 160 TOPS @ INT8 and 100 TFLOPS @ bFP16 physical compute power, paired with up to 48GB memory and 153.6 GB/s ultra-high bandwidth, with typical power consumption of only 10W — equivalent to a phone fast-charging power level — enabling PCs, intelligent voice devices, robots, and other smart mobile terminals to efficiently run local large models from 1.5B to 70B parameters, truly achieving "high compute power, low power consumption, plug and play."
Looking ahead, Houmo AI has initiated R&D on next-generation DRAM-PIM technology, embedding compute units directly into DRAM arrays to make compute-storage collaboration tighter and more efficient. This technology will break through 1 TB/s in-chip bandwidth, improving energy efficiency threefold over current levels, pushing hundred-billion-parameter large models toward widespread deployment on terminal devices, and enabling more powerful AI compute to integrate into everyday devices such as PCs and tablets.
06/
Maijie Translational Medicine PD-L1 Assay
Approved for Second Indication
Recently, the PD-L1 detection kit independently developed, registered, and produced by Qiming Venture Partners portfolio company Maijie Translational Medicine (Maipukang®, National Medical Device Registration No. 20223401300), following its approval for non-squamous non-small cell lung cancer, successfully gained approval for a second indication — as a companion diagnostic to help identify patients with esophageal squamous cell carcinoma eligible for first-line treatment with HANSIZHUANG® (Serplulimab, serplulimab injection), achieving dual-indication companion diagnostic status.
Maijie Translational Medicine's PD-L1 detection kit has demonstrated high concordance with imported antibodies across multiple cancer types, with similar pharmacodynamic data. Additionally, in a multi-center study for esophageal squamous cell carcinoma, it stood out among numerous domestic antibodies with high concordance to 22C3 staining and slightly higher sensitivity.
07/
Rendu Biotechnology Launches Chikungunya Virus
Nucleic Acid Detection Product (Fluorescence PCR Method)
Recently, an imported chikungunya fever outbreak occurred in Foshan, Guangdong Province. Qiming Venture Partners portfolio company Rendu Biotechnology (688193.SH) urgently launched a chikungunya virus nucleic acid detection product (fluorescence PCR method) to help disease control agencies and medical institutions comprehensively respond to further spread of the outbreak.
The product features high sensitivity with a detection limit as low as 100 copies/mL, enabling precise pathogen detection; rapid and efficient detection with amplification in just 70 minutes; internal controls monitoring the entire laboratory testing process to reduce false negative reporting; and compatibility with various extraction reagents or Rendu Biotechnology's matching extraction reagents.
Technology Strength
01/
WeRide and Lenovo Capital and Incubator Group Debut Vehicle with NVIDIA DRIVE
Thor Chip Powers 100% Automotive-Grade HPC 3.0 Computing Platform
Qiming Venture Partners portfolio company WeRide (NASDAQ: WRD) recently unveiled the HPC 3.0 high-performance computing platform, co-developed with Lenovo's vehicle computing division and built on NVIDIA's latest DRIVE Thor X chip. The platform made its debut on WeRide's next-generation Robotaxi, the GXR — making it the world's first Robotaxi to feature the NVIDIA DRIVE Thor X. The fully automotive-grade HPC 3.0 platform cuts the cost of WeRide's GXR autonomous driving suite by 50%, accelerating the path to large-scale commercial deployment.
"This deep collaboration with Lenovo Vehicle Computing and NVIDIA represents a critical breakthrough for us in computing power, system architecture, and cost control," said Tony Han, WeRide's founder and CEO. "Deploying the HPC 3.0 platform on the GXR not only enhances the reliability and response speed of our Robotaxi, but also dramatically reduces our commercial deployment costs. Going forward, we'll extend the HPC 3.0 platform to our other L4 autonomous products — including minibuses and sanitation vehicles — making autonomous driving technology accessible across all urban scenarios and serving more customers and users."
02/
UBTECH's Industrial Humanoid Robot Walker S2 Evolves with AI
BrainNet 2.0 and Co-Agent Build a Dual-Loop AI Architecture
Qiming Venture Partners portfolio company UBTECH (09880.HK) has launched the Walker S2, a full-size industrial humanoid robot designed for intelligent manufacturing. Through its upgraded BrainNet 2.0 architecture and the self-developed Co-Agent — the world's first intelligent agent technology purpose-built for industrial humanoid robot bodies — UBTECH has created an industrial-grade dual-loop AI system that enables continuous, spiraling evolution from single-unit autonomy to swarm coordination.
Standing 1.76 meters tall, the Walker S2 combines breakthrough hardware design with human-like gait and dexterous manipulation capabilities. It also features the world's first autonomous battery-swapping technology, enabling uninterrupted 24/7 operation.
03/
Galaxy Universal Becomes Exclusive Robotics Platform Sponsor of International AI Olympiad
Qiming Venture Partners portfolio company Galaxy Universal will serve as the exclusive robotics platform sponsor for the 2nd International Olympiad in Artificial Intelligence (IOAI 2025), enabling young people to practice AI technology in real-world scenarios and explore innovations in embodied intelligence.
Galaxy Universal is the exclusive technical sponsor for IOAI 2025's Team Challenge, providing a full-cycle competition platform from simulation to real-world deployment. Leveraging its global leadership in embodied intelligence, the company was formally invited by the international organizing committee to contribute to problem design and evaluation standards, bringing authoritative embodied intelligence engineering practice to the competition.
Galaxy Universal's self-developed embodied large-model robot Galbot will fully support the "Future Factory" challenge task, with participating students completing the entire workflow from task parsing to algorithm development to real-world deployment through a "simulation-to-real integration" approach.
04/
Cornerstone Robotics Enables Global Experts to Complete Tri-Continent Collaborative Remote Surgery
A transcontinental, three-way collaborative remote surgery was recently performed across Eurasia, enabled by the Sentire® laparoscopic surgical robot and dedicated remote network developed by Qiming Venture Partners portfolio company Cornerstone Robotics. The procedure was conducted simultaneously in Shanghai, Hong Kong, and London, with Cornerstone's technology providing highly stable technical support throughout.
The successful operation demonstrates that Cornerstone Robotics' surgical robot has achieved mature application capabilities in complex international network environments and multi-team collaborative clinical scenarios, laying a feasibility foundation for the broader accessibility of quality medical resources and cross-regional clinical collaboration.
05/
TINGSN Technology Intracardiac Echocardiography System Receives FDA Clearance
TINGSN Technology, a Qiming Venture Partners portfolio company, has received FDA clearance (K-number: K250913) for its self-developed intracardiac echocardiography (ICE) diagnostic system. This milestone marks the first time a Chinese high-end cardiac interventional imaging device has entered the world's most advanced medical market.
The FDA-cleared TINGSN ICE system comprises two core components: TINGSN FINDERS 2 and TINGSN Sonic Eyes 10 Eco. TINGSN FINDERS 2 is a portable color Doppler ultrasound diagnostic device that serves as the system's "brain," equipped with a high-definition imaging platform and intelligent analysis algorithms to provide precise imaging data for clinical use. TINGSN Sonic Eyes 10 Eco is a 10F intracardiac echocardiography diagnostic catheter with a miniaturized probe design that can navigate through blood vessels directly into the heart, providing real-time dynamic visualization of cardiac structure and blood flow to serve as "visual navigation" for interventional procedures.
06/
Pure Research Life Technology CEO Zheng Wang Presents at 2025 Brain Health Conference
Frontier Technology, AI, and Brain-Computer Interface Forum
During the 2025 Brain Health Conference, Dr. Zheng Wang, founder and CEO of Qiming Venture Partners portfolio company Pure Research Life Technology, delivered a keynote speech at the "Frontier Technology, Artificial Intelligence, and Brain-Computer Interface" forum.
Dr. Wang provided an in-depth analysis of how Pure Research's AI Navigator intelligent pilot system leverages large models to build a "human-in-the-loop" multi-agent collaborative framework. Through more than 25 sub-disease model agents and over 2,300 clinical research standard-related atomic agents at the foundational layer, the system precisely, compliantly, and efficiently empowers key scenarios including intelligent subject screening, clinical trial source data generation and quality control, research data automatic collection and eCRF entry, AE/SAE adverse signal identification and reporting, and clinical trial monitoring. This architecture allows machines to handle the vast majority of tedious and labor-intensive tasks, with human experts contributing at the final quality control stage — dramatically improving both the efficiency and quality of clinical trials.
07/
Infervision Surgical Planning AI Receives Dual EU CE MDR and UK UKCA Certification
Infervision, a Qiming Venture Partners portfolio company, has obtained EU CE MDR and UK UKCA registration certification for its surgical planning AI product — making it the world's first fully automated surgical reconstruction solution (requiring no manual operation) to receive triple certification from China, the UK, and Europe. This not only grants Infervision legal commercial authorization in the European market, but also marks another key breakthrough for the company in global surgery.
Infervision's AI system integrates advanced image recognition and deep learning technologies to generate high-precision 3D models within minutes, supporting the complete workflow from preoperative anatomical identification to intraoperative visualization. It also features intelligent surgical simulation tools that help physicians rapidly anticipate surgical challenges and risks. The system can be flexibly deployed on-premises or in the cloud, and seamlessly integrated into existing hospital workflows, providing powerful support for smart surgery in European hospitals.
08/
Inscintex at Shanghai Jiao Tong University
Chromatography System Technical Training
Recently, Inscintex, a Qiming Venture Partners portfolio company, was invited by the Instrument Sharing and Technology Service Platform at Shanghai Jiao Tong University's School of Life Sciences and Biotechnology to conduct a technical training session on chromatography systems.
The event combined theoretical lectures with hands-on practice, systematically covering purification chromatography principles, experimental method optimization, and the integration of experimental procedures with theory — deepening participants' understanding of chromatography technology and significantly improving their practical skills. This represents another important step for Inscintex in strengthening industry-university-research collaboration and advancing domestic scientific instrumentation.
09/
NeuroEchos Debuts LaserRO™ MRI-Guided Laser Ablation
Minimally Invasive Surgery System at Academic Annual Meeting
At the 8th Academic Annual Meeting of the CAAE Stereotactic Electroencephalography and Brain Localization Committee, NeuroEchos, a Qiming Venture Partners portfolio company, unveiled its upcoming LaserRO™ next-generation MRI-guided laser ablation minimally invasive surgery system.
Konstantin Slavin, President of the International Neuromodulation Society and Professor of Neurosurgery at the University of Illinois at Chicago, delivered a keynote speech in which he shared the clinical value of the LaserRO™ MRI-guided laser ablation minimally invasive surgery system and the Epilcure™ closed-loop neuromodulation system for precision epilepsy treatment.
10/
Just Medical Completes Live Surgery Debut of
Extreme Intelligence EPS® Total Knee Arthroplasty Robot
During the Artificial Intelligence Orthopedics Symposium and the 2025 Nantong University Affiliated Hospital Robot-Assisted Artificial Joint Replacement Forum, Just Medical, a Qiming Venture Partners portfolio company, performed the live surgery debut of its Extreme Intelligence EPS® total knee arthroplasty robot.
Developed from clinical needs and deeply aligned with cutting-edge surgical medicine, Just Medical's Extreme Intelligence EPS® total knee arthroplasty robot features boundary protection, gap balancing, precision registration, and accurate osteotomy — maximizing efficiency, precision, and safety in knee replacement surgery.
Corporate Honors
01/ Over 10 Qiming Venture Partners Portfolio Companies Named to 2025 AI Cloud 100 China List
Recently, the 2025 AI Cloud 100 China list was officially announced. The list aims to identify Cloud enterprises that have achieved genuine commercial deployment in generative AI (GenAI) and delivered significant economic returns. This year's list covers six segments: AI Infrastructure, AI Intelligent Insights, AI Productivity, AI Physical World, AI Services, and AI Content Generation.
Qiming Venture Partners portfolio companies Zhipu AI, Unisound (09678.HK), Infinigence AI, StepFun, XSKY, Xiaoe Tech, Shengshu Technology, Tongdun Technology, DeepWise, Fxiaoke, Kimatrix, and Galaxy Universal were named to the list. Among them, Xiaoe Tech and Shengshu Technology ranked first in the AI Services and AI Content Generation segments, respectively.
02/ Multiple Qiming Venture Partners Portfolio Companies Named to Ifenxi China AI Large Model Vendor Top 50 List
Recently, Ifenxi released its inaugural China AI Large Model Vendor Top 50 list. The list focuses on large model vendors' commercialization capabilities, using won bids as the core evaluation metric to select vendors with extensive project implementation experience, providing reference for enterprise users.
Qiming Venture Partners portfolio companies Zhipu AI, StepFun, Unisound (09678.HK), Huimei Technology, and UBTECH (09880.HK) were named to the list.
03/ Four Qiming Venture Partners Portfolio Company Founders Named to Cyzone 2025 Under-35 Entrepreneurship Pioneers List
Recently, Cyzone released its 2025 Under-35 Entrepreneurship Pioneers list. The list spotlights and inspires young entrepreneurs, capturing the most vibrant pulse of innovation in this era, and serves as an important barometer for identifying future business leaders and innovation trends.
Named to the list were Hao Liu, Co-founder and CTO of Tiangui Technology; Weijie Sun, Founder and CEO of DeepWise; Shuhao Wang, Co-founder and CTO of Tongche Future; and Zerun Wang, Co-founder, CTO, and COO of Cornerstone Robotics.
Past Issues
Qiming Weekly | Qiming Venture Partners Portfolio Company Funding and Updates Vol. 26, 2025
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management of $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns in their industries.
Among Qiming Venture Partners' portfolio companies, many have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, and Biren Technology.